Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.
NovaBiotics recognises that new, effective treatments are desperately needed to address these symptoms.
Our solution is Lynovex® (NM001), which is being developed to improve the quality & length of life of all CF patients – not just those with particular CFTR genotypes.
